Detalhe da pesquisa
1.
Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
Circulation
; 148(13): 989-999, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37624364
2.
Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
Circulation
; 141(11): 891-901, 2020 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31992063
3.
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Lancet
; 394(10205): 1243-1253, 2019 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31488372
4.
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.
Am Heart J
; 209: 97-105, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30703644
5.
Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.
Catheter Cardiovasc Interv
; 89(6): 994-1002, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27527508
6.
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Lancet
; 380(9852): 1482-90, 2012 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22951305
7.
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT.
Int J Cardiol
; 383: 24-32, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080466
8.
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
Cardiovasc Revasc Med
; 34: 3-10, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653633
9.
Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.
J Am Coll Cardiol
; 80(8): 766-778, 2022 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35981821
10.
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.
J Am Coll Cardiol
; 80(13): 1220-1237, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36137672
11.
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
Int J Cardiol
; 334: 37-41, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33887341
12.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
JACC Cardiovasc Interv
; 14(6): 639-648, 2021 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33727005
13.
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
J Am Heart Assoc
; 8(22): e013607, 2019 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31696762
14.
Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
JACC Cardiovasc Interv
; 12(17): 1665-1675, 2019 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422088
15.
Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Circ Cardiovasc Interv
; 11(9): e006741, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30354590
16.
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial.
EuroIntervention
; 14(6): 692-699, 2018 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29205157
17.
Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries?
Am J Cardiol
; 97(5): 603-5, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16490421
18.
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
JAMA Cardiol
; 1(7): 795-803, 2016 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27572001
19.
A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
JACC Cardiovasc Interv
; 9(1): 42-50, 2016 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26762910
20.
Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study.
J Cardiovasc Transl Res
; 9(1): 40-8, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26684009